Raising awareness of BNCT and expanding accelerator adoption

「The company signed a partnership agreement with SUMITOMO HEAVY INDUSTRIES,LTD. concerning the introduction of BNCT accelerators manufactured, developed and sold by the latter at medical institutions and other facilities in Japan, further strengthening its relationship with the company.」

「In Japan, the company continues to actively hold academic conferences and seminars related to relevant medical societies, build relationships with healthcare professionals, and work to increase the number of cases by raising awareness of BNCT.」

「A paper on an investigator-initiated specified clinical study of recurrent breast cancer conducted at Edogawa Hospital, which provides the company's drug formulation, was published in the electronic edition of Cureus. A paper on the treatment outcomes for unresectable locally recurrent or unresectable locally advanced head and neck cancer treated at the Kansai BNCT Joint Medical Center of Osaka Medical and Pharmaceutical University was also published in Cancer Medicine. In addition, a paper summarizing the efficacy and safety of BNCT based on treatment outcomes at the South Tohoku BNCT Research Center was published in Radiotherapy and Oncology.」

「The company also contributed to a serialized feature in PHARM TECH JAPAN, a specialist magazine covering pharmaceutical manufacturing and development. In addition, at the Embassy of France in Japan, the company met with the director of the research institute at Centre Léon Bérard in Lyon, France, who had expressed interest in the company's BNCT.」

「As part of its efforts to raise awareness of BNCT, the Company was able to improve its ability to attract patients by actively holding academic lectures and seminars related to relevant academic societies.」

「As part of its efforts to raise awareness of BNCT, the Company revamped part of its website, added explanatory content on BNCT titled “How to BNCT—Head and Neck Cancer Treatment from Japan,” and strengthened its dissemination of information on BNCT. The Company also actively held academic lectures and seminars related to relevant academic societies, promoting efforts to increase the number of BNCT cases.」

「As part of its efforts to expand the BNCT market in Japan, the Company entered into an agreement with Okayama University to conduct joint research on applying BNCT to melanoma, and further promoted its awareness-building activities by actively holding various seminars and online seminars hosted by the Company. These efforts to raise awareness of BNCT improved the Company's ability to attract patients to medical institutions, resulting in revenue of ¥175.169 million for the cumulative third quarter (up 106.8% year on year)」

「In addition, at a side event of the IAEA (International Atomic Energy Agency) General Conference held on 26 September, the Company presented a drug for BNCT. BNCT, for which treatment began in Japan, has attracted attention within the IAEA from the perspectives of the peaceful use of nuclear energy and contributions to medicine. Japan hosted a session on BNCT, and the Company was the only pharmaceutical company to participate, contributing to greater awareness of BNCT and the Company. The Company also entered into an agreement to cooperate in an investigator-initiated specified clinical study aimed at more accurately assessing the efficacy of BNCT in treating recurrent malignant glioma in Japan using PET (positron emission tomography) scans, and further promoted its awareness-building activities by actively holding various seminars and online seminars hosted by the Company.」

「Under these circumstances, to promote its overseas business, the Company entered into a new agreement with SUMITOMO HEAVY INDUSTRIES,LTD. to further strengthen the existing alliance by clarifying the scope of joint marketing activities and the compensation for supporting the Company's activities, thereby enabling the two companies to work flexibly together on sales activities for introducing accelerators for BNCT treatment, and」

「In August of the same year, the Company entered into a business alliance agreement with HIMEDIC Co., Ltd., a subsidiary of RESORTTRUST,INC., to strengthen cooperation between the two companies and actively pursued initiatives to raise awareness of BNCT, including joint seminars at relevant academic societies and online seminars.」

「In August of the same year, the Company entered into a business alliance agreement with HIMEDIC Co., Ltd., a subsidiary of RESORTTRUST,INC., to strengthen cooperation and advance initiatives aimed at further promoting BNCT.」

「In August of the same year, the Company entered into a business alliance agreement with HIMEDIC Co., Ltd., a subsidiary of RESORTTRUST,INC., to strengthen cooperation and advance initiatives aimed at further promoting BNCT.」

「Against this backdrop, the Company has worked to raise awareness of BNCT and further expand its business.」

「In Japan, the Company will develop its business with the aim of raising awareness of BNCT as a medical technology and of treatment outcomes, while promoting the adoption of accelerators. To raise awareness, the Company will enhance the provision of medical information on the efficacy and safety of Steboronin® through visits to medical institutions, universities and other research institutions, and will pursue more effective business activities through academic conferences and seminars.」